AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $9.98, up 2.25% on the session, giving a market capitalisation of $3.05B. On trailing twelve-month figures it carries a trailing P/E of -18.48, a net margin of -248.8%. Its beta of 1.19 implies it has historically moved more than the broad market.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
AbCellera Biologics Inc. is most often compared with the following Healthcare names: